In vitro evaluation suggests fenfluramine and norfenfluramine are unlikely to act as perpetrators of drug interactions

Parthena Martin1 | Maciej Czerwiński2 | Pallavi B. Limaye2 | Brian W. Ogilvie2
Steven Smith1 | Brooks Boyd1

Abbreviations: ABC, ATP-binding cassette transporter; ASM, antiseizure medication; AUC, area under the concentration curve; BCRP, breast cancer resistance protein; BEH, ethylene bridged hybrid; CDD, CDKL5 deficiency disorder; C max, maximum drug concentration; CYP450, cytochrome P450; DDI, drug–drug interaction; DMSO, dimethyl sulfoxide; DS, Dravet syndrome; EC 50, concentration of half-maximal response; EDTA, ethylenediaminetetraacetic acid; E max, maximum induction effect; FDA, United States Food and Drug Administration; FFA, fenfluramine; f unbound, fraction unbound; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HEK, human embryonic kidney cell; IC 50, potency of inhibition (concentration of 50% inhibition); I max, maximum unbound systemic plasma concentration of an inhibitor; K m, Michaelis-Menten rate constant; LC-MS/MS, liquid chromatography/tandem mass spectrometry; LDH, lactate dehydrogenase; LGS, Lennox-Gastaut syndrome; LIMS, laboratory information management system; MATE, multidrug and toxin extrusion; MDCKII, Madin-Darby canine kidney cell; MgCl 2, magnesium chloride; mRNA, messenger RNA; NADPH, nicotinamide adenine dinucleotide phosphate; nFFA, norfenfluramine; OAT, organic anion transporter; OCT, organic cation transporter; PDS, phosphate buffered saline; PCR, polymerase chain reaction; P-gp, P-glycoprotein multidrug transporter; qRT-PCR, quantitative reverse transcription-polymerase chain reaction; R f, the predicted ratio of FFA’s AUC in the presence of an inhibitor; R i, the predicted ratio of FFA’s AUC in the presence or absence of an inhibitor; RED, rapid equilibration dialysis; S max, substrate concentration at 50% V max; SD, standard deviation; SEM, standard error of the mean; SLC, solute carrier transporter; V max, maximum rate of reaction; ΔΔCT, change in threshold cycles.

Abstract
Studies support the safety and efficacy of fenfluramine (FFA) as an antiseizure medication (ASM) in Dravet syndrome, Lennox-Gastaut syndrome, or CDKL5 deficiency disorder, all pharmacoresistant developmental and epileptic encephalopathies. However, drug–drug interactions with FFA in multi-ASM regimens have not been fully investigated. We characterized the perpetrator potential of FFA and its active metabolite, norfenfluramine (nFFA), in vitro by assessing cytochrome P450 (CYP450) inhibition in human liver microsomes, CYP450 induction in cultured human hepatocytes, and drug transporter inhibition potential in permeability or cellular uptake assays. Mean plasma unbound fraction was ~50% for both FFA and nFFA, with no apparent concentration dependence. FFA and nFFA were direct in vitro inhibitors of CYP2D6 (IC 50 4.7 and 16 μM, respectively) but did not substantially inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP3A4/5. No time- or metabolism-dependent CYP450 inhibition occurred. FFA and nFFA did not induce CYP1A2; both induced CYP2B6 (up to 2.8-fold and up to 2.0-fold, respectively) and CYP3A4 (1.9- to 3.0-fold and 3.6- to 4.8-fold, respectively). Mechanistic static pharmacokinetic models predicted that neither CYP450 inhibition nor induction was likely to be clinically relevant at doses typically used for seizure reduction (ratio of area under curve [AUCR] for inhibition <1.25; AUCR for induction >0.8). Transporters OTC2 and MATE1 were inhibited by FFA (IC 50 19.8 and 9.0 μM) and nFFA (IC 50 5.2 and 4.6 μM) at concentrations higher than clinically achievable; remaining transporters were not inhibited. Results suggest...
that FFA and nFFA are unlikely drug–drug interaction perpetrators at clinically relevant doses of FFA (0.2–0.7 mg/kg/day).

**KEYWORDS**
Dravet syndrome, drug transporter, drug–drug interactions, fenfluramine, perpetrator potential

---

**Significance statement**

Fenfluramine demonstrated efficacy for reducing convulsive seizure frequency in patients with Dravet syndrome and other developmental and epileptic encephalopathies. These patients typically take multiple concurrent antiseizure medications, emphasizing the importance of evaluating fenfluramine’s drug–drug interaction potential. We characterized the perpetrator potential of fenfluramine and its active metabolite, norfenfluramine, in vitro by assessing cytochrome P450 (CYP450) inhibition and induction, as well as drug transporter inhibition potential. Mechanistic static pharmacokinetic models confirm minimal perpetrator potential. A companion paper evaluates fenfluramine’s victim potential.
2 | MATERIALS AND METHODS

2.1 | Chemicals

The CYP450 substrates phenacetin, diclofenac, dextromethorphan, midazolam, and testosterone were obtained from Sigma-Aldrich (St. Louis, MO); efavirenz and amodiaquine from the US Pharmacopeia (Rockville, MD); and S-mephenytoin from Toronto Research Chemicals (Toronto, Ontario, Canada). Substrate metabolites 4′-hydroxy-diclofenac and 6β-hydroxytestosterone were obtained from Sigma-Aldrich; acetaminophen, N-desethylamodiaquine, 4′-hydroxydiazepam, dextromethorphan, and 1′-hydroxymidazolam from Cerilliant (Round Rock, TX); and 8-hydroxyefavirenz from Toronto Research Chemicals. Internal standards for all CYP450 bioanalytical assays were as follows: acetaminophen-d₄ (Cerilliant Corporation), 8-hydroxyefavirenz-d₄ (Toronto Research Chemicals), N-desethyl-amodiaquine-d₉ (Toronto Research Chemicals), 4′-hydroxydiclofenac-d₄ (TLC Pharmaceutical Standards, Aurora, Ontario, Canada), 4′-hydroxydiazepam-d₅ (TLC Pharmaceutical Standards), dextromethorphan-d₃ (Toronto Research Chemicals), 1′-hydroxymidazolam-d₄ (Cerilliant Corporation), and 6β-hydroxy-testosterone-d₃ (Cerilliant Corporation). The α-naphthoflavone, orphenadrine, modafinil, quinidine, and ketoconazole used as positive controls for direct inhibition of CYP450s were obtained from Sigma-Aldrich; montelukast from Sequoia Research Products (Pangbourne, United Kingdom); and sulfaphenazole from Santa Cruz Biotechnology (Dallas, TX). Tienilic acid (Cypex, Ltd., Dundee, Scotland), esomeprazole (Toronto Research Chemicals), furylphenidine, phenylcyclohexane, paroxetine (Sigma-Aldrich), treleandomycin (Enzo Life Sciences, Farmingdale, NY), and gemfibrozil glucuronide (XenoTech, Kansas City, KS) were used as positive controls for metabolism-dependent CYP450 inhibition. Components of the NADPH-generating system ([β]-NADP, glucose-6-phosphate, glucose-6-phosphate dehydrogenase) were obtained from Sigma-Aldrich. FFA hydrochloride and nFFA hydrochloride—[1-(3-trifluoromethyl) phenyl] propan-2-amine hydrochloride—were obtained from Zogenix, Inc. (Emeryville, CA). Flumazenil, omeprazole, phenobarbital, and rifampin used in CYP450 induction studies were obtained from Sigma-Aldrich.

For studies examining cell membrane transporters, the following agents were all obtained from Sigma-Aldrich: digoxin, valspsodar, verapamil, prazosin, Ko143, estradiol-17β-glucuronide, rifampin, cyclosporine, butyric acid, p-aminohippuric acid, probenecid, novobiocin, estrone-3-sulfate, ibuprofen, and quinidine. Digoxin-d₄ and prazosin-d₈ were obtained from Toronto Research Chemicals; lopinavir from the European Pharmacopoeia (Strasbourg, France); [3H]-p-aminohippuric acid from American Radiolabeled Chemicals (St. Louis, MO); [3H]-estradiol-17β-glucuronide and [3H]-estrone-3-sulfate from PerkinElmer (Hopkinton, MA, USA); and [14C]-metformin from Moravek, Inc. (Brea, CA).

2.2 | Direct CYP450 inhibition

Inhibition of CYP450s by FFA and nFFA was assessed according to methods described previously. Microsomes from non-transplantable human livers were prepared and characterized as outlined previously. A mixed-gender pool of 200 individual human liver microsomal samples was used. Substrate concentrations and incubation conditions for determination of the kinetic constant (Kₘ or S₄₀) used to select marker substrate concentrations were previously determined. FFA and nFFA were each evaluated for ability to inhibit the following CYP450-selective reactions in a direct, time-dependent, and metabolism-dependent manner: CYP1A2, phenacetin O-dealkylation; CYP2B6, efavirenz 8-hydroxylation; CYP2C8, amodiaquine N-dealkylation; CYP2C9, diclofenac 4′-hydroxylation; CYP2C19, S-mephenytoin 4′-hydroxylation; CYP2D6, dextromethorphan O-demethylation; CYP3A4/5, midazolam 1′-hydroxylation; and CYP3A4/5, testosterone 6β-hydroxylation.

Aliquots of FFA or nFFA solutions were added to buffer (pH 7.4) containing potassium phosphate buffer (50 mM), MgCl₂ (3 mM), and EDTA (1 mM). Incubations to measure CYP450 enzyme activity were conducted at approximately 37°C in 200-µL incubation mixtures containing the buffer mixture described previously, an NADPH-generating system (mixture of the following: NADP [1 mM], glucose-6-phosphate [5 mM], glucose-6-phosphate dehydrogenase [1 Unit/mL]), and a concentration of marker substrate based on the Kₘ or S₄₀ determined previously. Concentrations of FFA ranged from 0.06–60 µM for all CYP450 enzymes examined except for CYP3A4/5. CYP3A4/5 inhibition was measured using higher concentrations of FFA ranging from 0.6–600 µM with the intention of identifying the potential of this test article to cause interactions with CYP3A4/5 in the intestine after oral administration. Concentrations of nFFA ranged from 0.1–100 µM. Detailed analytical and statistical methods for determining the degree of inhibition can be found in the Supplemental Material.

2.3 | Metabolism-dependent CYP450 inhibition

To examine metabolism-dependent inhibition of the CYP450 enzymes, FFA and nFFA were preincubated in duplicate at 37 ± 1°C with human liver microsomes as described above for ~30 min in the presence of an NADPH-generating system, which allowed for the generation of potential intermediates that could irreversibly inhibit human CYP450 enzymes. For comparison, additional duplicate samples containing FFA or nFFA were preincubated for 30 min in the absence of NADPH. These preincubations allowed assessment of the NADPH-dependence of any time-dependent CYP450 inhibition. Following the 30-min preincubation, the NADPH-generating system and/or marker substrate was added, and incubations were continued as described previously to measure residual CYP450 enzyme activity. Incubations that contained FFA and nFFA but were not preincubated served as negative controls for time-dependent CYP450 inhibition.

2.4 | Red blood cell/plasma partition

To determine the extent of red blood cell accumulation of FFA and nFFA, the red blood cell/plasma partition of both drugs was assessed.
in human blood obtained from BioIVT (Westbury, NY). Fresh reference plasma was separated from whole blood by centrifugation at 2000 × g (5 min, 4°C). FFA or nFFA (2 μM in dimethyl sulfoxide [DMSO]) or the reference assay control (chloroquine) was incubated in both whole blood and reference plasma (60 min, 37°C; final DMSO concentration, 0.1%) and was centrifuged (2000 × g; 5 min, 4°C). Plasma (30 μL) was aliquoted to multiwell plates and was quenched with 300 μL of 50% acetonitrile, 50% methanol, and 0.05% formic acid solution containing internal standards (bucetin and warfarin). Plates were vortexed and centrifuged (4000 RPM, 15 min, 4°C); supernatants were transferred to fresh plates for quantification by liquid chromatography/tandem mass spectrometry (LC-MS/MS; API 4000 [AB Sciei, Framingham, MA] coupled to a Shimadzu LC-20AD LC pump system [Shimadzu Scientific Instruments, Columbia, MD] using Atlantis T3 dC18 reverse phase HPLC columns [Waters Corporation, Milford, MA]; 20 μm × 2.1 mm; flow rate: 0.5 mL/min; 3-min gradient starting and ending with 98% solvent A, where the mobile phase consisted of solvent A—0.1% formic acid in water, and solvent B—0.1% formic acid in acetonitrile). Red blood cell-to-plasma ratio was calculated as follows:

\[
\text{KRBC/PL} = \frac{1}{H} \left( \frac{C_p}{C_b} - 1 \right) + 1.
\]

where:

- \( H \) = hematocrit (percent of total blood cells in whole blood sample, v/v).
- \( C_p \) = ratio of peak areas of the analyte over internal standard in reference plasma.
- \( C_b \) = ratio of peak areas of the analyte over internal standard in top plasma layer separated from whole blood (i.e., concentration in the plasma layer after centrifugation of blood samples, not concentration in the blood).

### 2.6 | Protein binding

FFA and nFFA were each added to triplicate samples of pooled rat, dog, and human plasma (final concentrations, 10 and 100 ng/mL). In vitro plasma protein binding was then determined by using the Rapid Equilibrium Device (RED) with a molecular weight cutoff of 8 kDa (Thermo Fisher Scientific, Inc., Waltham, MA). The warfarin positive control was added to separate samples of pooled human plasma for a final concentration of 10 μM. The internal standard was niflumic acid. FFA and nFFA (1 and 10 ng/mL each) were added to plasma of each species, mixed gently, and stored in an ice bath until subsequent analysis. Protein binding was determined by adding a 300-μL aliquot of the test sample or the control sample to the sample chamber of the RED and adding a 500-μL aliquot of PBS (pH 7.4) to the buffer chamber. The device unit was sealed and incubated at 37°C for 4 h with gentle shaking (~750 rpm). After dialysis, three aliquots of the test samples (50 μL) were collected from both sample and buffer chambers and were mixed with 50 μL of methanol as “donor samples” and “acceptor samples,” respectively. Initial plasma samples and donor samples, acceptor samples, samples for calibration curves, and samples for positive control were spiked with the internal standard and were subjected to LC-MS/MS quantification of FFA and nFFA. Concentrations for test samples were determined by regression from peak area values obtained from standard curves (FFA, 0, 1, 3, 10, 30, 100, and 300 ng/mL; nFFA, 0.1, 0.3, 1, 3, 10, 30, and 100 ng/mL). A detailed description of the LC-MS/MS process can be found in the Supplemental Material. Supernatant fractions were analyzed by LC-MS/MS using an Acquity Ultra Performance Liquid Chromatography system with ethylene bridged hybrid (BEH) C18 columns (2.1 × 50 mm, 1.7 μm; Waters Corporation; Milford, MA) coupled to an API4000 mass spectrometer (AB Sciei). Calibration curves were determined by dissolving FFA or nFFA in methanol to prepare curves of 0, 1, 3, 10, 30, 100, and 300 ng/mL for FFA, and 0, 0.1, 0.3, 1, 3, 10, 30, and 10 ng/mL for nFFA. Samples were prepared
in triplicate and were dialyzed for 4 h. Peak area values were obtained from LC-MS/MS chromatograms corresponding to the analyte and the internal standard. Analyst software (v. 1.4.2; AB Sciex) was used to calculate a regression equation based on the calibration curve by weighted least squares and concentrations of analyte in the samples. Protein binding was calculated as follows:

\[
\text{Protein binding ratio (\%) = 100 – Unbound ratio (\%)},
\]

where

\[
\text{Unbound ratio (\%) = } \frac{\text{Accepter Sample Concentration}}{\text{Donor Sample Concentration}}.
\]

2.7 Transporter inhibition

FFA and nFFA were evaluated as inhibitors of the human ATP-Binding Cassette Transporters (ABC) BCRP and P-gp and the Solute Carrier (SLC) transporters OAT1, OAT3, OCT2, MATE1 and MATE2-K, OATP1B1, and OATP1B3, according to published methods (Supplemental Table 1).\(^{28}\) FFA and nFFA were evaluated as inhibitors of the P-gp transporter in Caco-2 cells (American Type Culture Collection, Manassas, VA) and of the BCRP transporter in MDCKII-BCRP cells (Netherlands Cancer Institute, Amsterdam, Netherlands). For remaining transporters, HEK293 cells transported with transporter-specific viral vectors (Sekisui Medical Co. Ltd., Tokyo, Japan) were used to assess FFA and nFFA inhibitory effects as described.\(^{29}\) The test compound (FFA or nFFA) or the positive control substrate (digoxin and prazosin for BCRP and P-gp transporters, respectively) was added to the donor chamber. Samples were collected from the receiver compartment at 15, 30, and 120 min, mixed with an internal standard, and analyzed for FFA, nFFA, or control substrate by LC-MS/MS. For uptake transporter inhibition studies, transporter-transfected cells and control cells were preincubated in medium containing FFA, nFFA, positive control, or solvent control for 15 min, followed by a second incubation in the presence of a radiolabeled probe substrate for 1 to 2 min. Cells were then washed, lysed with scintillation cocktail, and analyzed for the probe substrate with a MicroBeta scintillation counter (PerkinElmer, Hopkinton, MA). Transcellular transporter assay conditions are described in Supplemental Table 1. Calculation of IC\(_{50}\) values was based on bidirectional permeability of probe substrate with and without the inhibitor in MDCKII cells expressing BCRP and in Caco-2 cells expressing P-gp, and transporter-dependent uptake of probe substrate in HEK293 cells expressing all other transporters (Supplemental Table 1).

2.8 Statistical analysis and data analysis

Summary data are expressed as percent of control and mean ± standard deviation (SD) or standard error of the mean (SEM), as appropriate. Individual values from inhibition studies were processed with the laboratory information management system (LIMS) Galileo v3.3 (Thermo Fisher Scientific), which was used to calculate IC\(_{50}\) values from a four-parameter logistic regression applied to percent inhibition versus concentration values. For induction data, IC\(_{50}\) and \(E_{\text{max}}\) were obtained by applying the fitting algorithm in SigmaPlot 12.5 to fold-increase and concentration values to obtain the best-fit three-parameter logistic function. Based on FDA guidance for metabolism- and transporter-mediated DDI studies,\(^{15}\) basic kinetic models for transporter inhibition, CYP450 inhibition, and CYP450 induction were employed to calculate R, \(R_1\), and \(R_3\) values, respectively, and were compared to the respective predetermined threshold values listed in the guidance document.\(^{15}\) Mechanistic static models for CYP450 inhibition and induction were employed to calculate AUCR and were compared to threshold values (AUCR >1.25 to denote inhibition and AUCR <0.8 to denote induction).\(^{15}\) The model assumed a maximum daily dose of 26 mg/day FFA base administered in a twice-daily dose of 13 mg and 100% metabolism by the target CYP450s (Supplemental Table 2). In clinical studies, FFA was administered twice daily as FFA HCI oral solution (2.2 mg/mL FFA base).\(^{2,3}\) Plasma protein binding data were used to estimate input parameters for fraction unbound to plasma proteins in the mechanistic static model (Supplemental Table 2). The fraction absorbed was assumed to be 100%, yielding the highest possible portal concentrations. The \(k_s\) was assumed to be 0.69/h for FFA. Based on population pharmacokinetic studies, maximum plasma concentrations of 68 and 37.8 ng/mL were used as model parameters for nFFA and FFA, respectively (Prescribing information: https://www.fintepla.com/). Assays were performed in duplicate or triplicate according to previously published reports. Statistical analysis for replicates was not possible with \(n=2\) sample sizes.

2.9 Nomenclature of targets and ligands

Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY,\(^{30}\) and are permanently archived in the Concise Guide to PHARMACOLOGY 2021/22\(^{31-33}\) and the IUPHAR/BPS Guide to Pharmacology Database.\(^{1}\)

3 RESULTS

3.1 Plasma protein binding

Protein binding of the positive control, 10 µM warfarin, was 99.5 ± 0.2% in human plasma, in close agreement with published data.\(^{3,24}\) Mean plasma unbound fraction FFA at 10 or 100 ng/mL in human plasma was 55.2 ± 7.8% and 49.9 ± 1.8%, respectively. Mean nFFA unbound fraction at 10 or 100 ng/mL was 50.3 ± 12.7% and 52.0 ± 2.0%, respectively. The unbound fraction of FFA and nFFA in rat or dog plasma was in the range of 37.8 ± 8.6% to 53.8 ± 2.2% and 44.5 ± 7.2% to 56.2 ± 6.8%, respectively. Recovery of FFA and nFFA
ranged from 72.2 ± 1.4% to 115.9 ± 11.1% (all species). Thus, plasma protein binding was approximately 50% for both FFA and nFFA in human plasma.

### 3.2 | CYP450 inhibition

The inhibitory effects of FFA and nFFA on CYP450 enzymes in terms of IC₅₀, percentage of inhibition, R₁ values calculated for the basic model of reversible inhibition, and AUCR values calculated for the static mechanistic model are shown in Table 1. The calculated R₁ value is the ratio of intrinsic clearance values of a probe substrate for an enzymatic pathway in the absence and in the presence of FFA or nFFA. Static mechanistic models incorporate more detailed drug disposition and drug interaction mechanisms for both interacting and substrate drugs. Under experimental conditions measuring direct enzyme inhibition, all FFA IC₅₀ values for CYP1A2, CYP2B6, CYP2C8, CYP2C9, and CYP2C19 were above 60 µM—the highest concentration of the drug tested. FFA inhibited these enzymes by 2.4%–14%. FFA directly inhibited 90% of CYP2D6 activity with an IC₅₀ of 4.7 ± 0.2 µM (Figure 1A). FFA IC₅₀ values for CYP3A4/5 were above 600 µM, the highest concentration of drug tested, for both of the CYP3A4/5 substrates, namely, midazolam and testosterone. FFA inhibited up to 18% of CYP3A4/5 testosterone 6β hydroxylase activity. All nFFA IC₅₀ values for CYP1A2, CYP2B6, CYP2C8, CYP2C9, and CYP2C19 were above 100 µM—the highest concentration tested. nFFA inhibited these enzymes by 2.9%–23%. nFFA directly inhibited 82% of CYP2D6 activity, with IC₅₀ of 16 ± 1 µM (Figure 1C). nFFA inhibited up to 2.8% of CYP3A4/5 testosterone 6β hydroxylase activity. Under experimental conditions to measure time- or metabolism-dependent inhibition, FFA and nFFA did not have any additional inhibitory effects on CYP450 enzyme activity compared to direct inhibition (Figure 1B, D for CYP2D6).

FFA and nFFA potential to inhibit CYP450 enzymes in the clinic was evaluated initially with the basic model and then with the static mechanistic model. Calculated FFA or nFFA R₁ values for CYP1A2, CYP2B6, CYP2C8, CYP2C9, and CYP2C19 were below the threshold level of 1.02, indicating that FFA and nFFA had only minimal potential to inhibit these enzymes in vivo (Table 1).

FFA and nFFA R₁ values for CYP2D6 (1.07 and 1.01, respectively. Since the FFA value was greater than the basic model threshold value and indicated its potential to inhibit the enzyme in the clinic, the potential of FFA and nFFA to inhibit CYP2D6 was investigated further with the static mechanistic model. In this model, the predicted AUCR of an index substrate in the presence and in the absence of FFA equaled 1.17, and was lower than the threshold value of 1.25, indicating that a clinical study of FFA inhibition potential for CYP2D6 is unlikely to be necessary. The nFFA CYP2D6 AUCR value was 1.01, indicating that a clinical study of nFFA inhibition potential was also unlikely to be necessary.

![Figure 1](image-url). Direct, but not time- or metabolism-dependent, inhibition of CYP2D6 (dextromethorphan O-demethylation) in human liver microsomes by fenfluramine (A, B) or norfenfluramine (C, D). Assays were conducted (A, C) without a 30-min preincubation or (B, D) with a 30-min preincubation in the presence (open circles) or absence (open triangles) of NADPH.
The FFA potential to inhibit intestinal CYP3A4/5 was evaluated with the basic model. The calculated $R_{1,gut}$ value was $<1.8$ and was lower than the threshold value of 11, indicating that clinically relevant inhibition of CYP3A4/5 in the gut by FFA was unlikely.

### 3.3 | CYP induction

At the time of isolation for cryopreservation, the viability of hepatocyte preparations used for induction assays was between 81.7% and 91% (Supplemental Table 3). Cells treated with vehicle (DMSO), flumazenil, or known CYP450 inducers exhibited normal hepatocyte morphology. No morphological changes were noted in hepatocytes treated with up to 40 $\mu$M FFA or 50 $\mu$M nFFA for 3 consecutive days. Treatment with up to 40 $\mu$M FFA or 50 $\mu$M nFFA caused little LDH release ($<8.5\%$ or $<13.8\%$ positive control, respectively) in all three hepatocyte cultures.

Cultured human hepatocytes were treated with FFA or nFFA to evaluate effects of both drugs on induction of CYP1A2, CYP2B6, and CYP3A4 mRNA expression (Table 2; Figure 2). The positive control inducers caused expected increases in CYP mRNA expression in cultures of human hepatocytes. Omeprazole (50 $\mu$M), phenobarbital (750 $\mu$M), and rifampin (20 $\mu$M) caused increases ranging from 32.7- to 52.5-fold, from 8.12- to 11.8-fold, and from 32.0- to 107-fold in CYP1A2, CYP2B6, and CYP3A4 mRNA levels, respectively (Figure 2). In all three hepatocyte cultures, both FFA (up to 40 $\mu$M) and nFFA (50 $\mu$M) had little or no effect (<2-fold change and <20% as effective as the positive control, omeprazole) on CYP1A2 mRNA levels. FFA and nFFA changed CYP1A2 mRNA levels from 1.24- to 1.54-fold and from 1.74- to 1.92-fold, respectively (Table 2). These values, according to the fold-change method, indicate lack of potential to induce the enzyme in vivo.\(^{15}\) No further estimates were conducted for CYP1A2.

Induction of CYP2B6 mRNA expression ranged from 2.05-fold to 3.77-fold above solvent control for FFA, and from 2.15-fold to 3.01-fold for nFFA (Table 2; Figure 2), both of which are above the 2-fold threshold set by FDA for potentially clinically relevant enzyme induction.
induction. Fold-increases in CYP3A4 mRNA levels caused by FFA and nFFA ranged from 2.86-fold to 3.95-fold for FFA and from 4.57-fold to 5.75-fold for nFFA, which are above the FDA-specified threshold (Table 2; Figure 2).

To further investigate the potential for FFA and nFFA to induce CYP2B6 and CYP3A4 clinically, basic kinetic and static mechanistic models were applied. $E_{\text{max}}$ and $EC_{50}$ parameters for effects of FFA and nFFA on the fold-increase in CYP2B6 and CYP3A4 mRNA were estimated from sigmoidal three-parameter equations. The parameters were applied to calculate $R_3$ and AUCR values for the basic kinetic and static mechanistic models, respectively (Table 2; Supplemental Table 2). The $R_3$ value predicted CYP2B6 induction by FFA in two of three hepatocyte cultures but did not predict CYP2B6 induction by nFFA (Table 2). The basic kinetic model predicted CYP3A4 induction by FFA in two hepatocyte cultures, and by nFFA in one hepatocyte culture. With the static mechanistic model, neither FFA nor nFFA was predicted to induce CYP2B6 or CYP3A4 enzymes in vivo (Table 2).

**Table 2**: Evaluation of Fenfluramine (FFA) and norfenfluramine (nFFA) potential to induce CYP1A2, CYP2B6, or CYP3A4 mRNA in vivo

|          | FFA HC10-10 | HC10-8 | HC7-8 | nFFA HC10-10 | HC10-8 | HC7-8 |
|----------|-------------|--------|-------|--------------|--------|-------|
| **CYP1A2** |             |        |       |              |        |       |
| Fold-change method | Fold changea | 1.24 | 1.54 | 1.54 | 1.86 | 1.92 | 1.74 |
| % of controlb | 0.55 | 1.04 | 1.72 | 1.96 | 1.79 | 2.35 |
| Potential to induce | No | No | No | No | No | No |
| **CYP2B6** |             |        |       |              |        |       |
| Fold-change method | Fold change | 2.09 | 3.77 | 2.05 | 2.54 | 3.01 | 2.15 |
| % of control | 15.3 | 29.10 | 9.66 | 21.60 | 21.20 | 10.60 |
| Potential to induce | Yes | Yes | Yes | Yes | Yes | Yes |
| Basic kinetic model | $E_{\text{max}}$ (fold)c | 1.21 ± 0.21 | 2.80 ± 0.20 | 0.94 ± 0.10 | 1.36 ± 0.11 | 2.08 ± 0.197 | 1.14 ± 0.083 |
| $EC_{50}$ (µM) | 4.61 ± 3.3 | 13.6 ± 1.5 | 8.32 ± 2.1 | 8.81 ± 1.6 | 26.4 ± 2.9 | 10.8 ± 2.3 |
| $R_3$ | 0.76 | 0.77 | 0.87 | 0.88 | 0.93 | 0.92 |
| Potential to induce | Yes | Yes | No | Yes | Yes | Yes |
| Static mechanistic model | AUCRd | 0.92 | 0.93 | 0.96 | 0.99 | 0.99 | 0.99 |
| Potential to induce | No | No | No | No | No | No |
| **CYP3A4** |             |        |       |              |        |       |
| Fold-change method | Fold change | 2.86 | 3.95 | 3.77 | 4.57 | 5.75 | 4.91 |
| % of control | 2.53 | 9.50 | 2.60 | 4.85 | 15.30 | 3.68 |
| Potential to induce | Yes | Yes | Yes | Yes | Yes | Yes |
| Basic kinetic model | $E_{\text{max}}$ (fold) | 2.30 ± 0.43 | 3.02 ± 0.25 | 2.69 ± 0.52 | 3.61 ± 0.40 | 6.95 ± 1.0 | 3.92 ± 0.048 |
| $EC_{50}$ (µM) | 9.05 ± 3.6 | 20.4 ± 1.9 | 8.53 ± 4.3 | 17.1 ± 3.9 | 37.8 ± 5.6 | 12.9 ± 0.38 |
| $R_3$ | 0.74 | 0.82 | 0.70 | 0.84 | 0.86 | 0.79 |
| Potential to induce | Yes | No | Yes | No | No | Yes |
| Static mechanistic model | AUCR | 0.92 | 0.95 | 0.90 | 0.96 | 0.97 | 0.95 |
| Potential to induce | No | No | No | No | No | No |

Purple: data relating to the basic kinetic model. Blue: data relating to the static mechanistic model.

aFold-change in mRNA concentration at highest dose tested (40 µM fenfluramine and 50 µM norfenfluramine).
bPercent of positive control induction of mRNA.
c$E_{\text{max}}$ and $EC_{50}$ and respective standard errors were calculated from the plot of drug concentrations vs fold-change $−1$ values of drug effect with Sigmoid, 3-parameter equation (SigmaPlot).
dCalculated as per FDA Guidance (2020).
FIGURE 2  Effects of various concentrations of fenfluramine (FFA), norfenfluramine (nFFA), or control on CYP1A2, CYP2B6, and CYP3A4 mRNA levels. Primary human hepatocyte cultures from three donors were incubated for 72 h with medium containing 0−40 µM FFA, 0−50 µM nFFA, or positive and negative controls. Levels of CYP1A2 mRNA (A), CYP2B6 mRNA (B), and CYP3A4 mRNA (C) were measured by quantitative polymerase chain reaction and were normalized first to the levels of glyceraldehyde 3-phosphate dehydrogenase mRNA, and then to the levels of corresponding CYP450 mRNAs in vehicle control cultures, as described in Materials and Methods. Hashed lines indicate 2-fold induction threshold.
3.4 | Transporter inhibition

The IC_{50} values characterizing inhibition of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, OCT2, MATE1, and MATE2-K transporters by FFA and nFFA, as well as the FDA recommended criteria for evaluation of drug transporter inhibition, namely, the formulae for R values and their cutoffs, are presented in Table 3.\textsuperscript{15} Estimated IC_{50} values were above the highest concentrations of FFA and nFFA examined for all transporters, with the exception of OCT2 and MATE1. FFA inhibited OCT2 and MATE1 transporters, with IC_{50} values of 19.8 and 9.0 \mu M, respectively (Figure 3A, B). nFFA inhibited OCT2 and MATE1 transporters, with IC_{50} values of 5.2 and 4.6 \mu M, respectively (Figure 3C, D). The potential of FFA and nFFA to inhibit drug transporters in vivo was evaluated by calculating the R values and comparing them with their predetermined cutoff values. Calculated R values for both FFA and nFFA for all drug transporters examined were below their respective cutoff values, indicating lack of potential to inhibit the transporters in vivo.

4 | DISCUSSION

This study evaluated FFA and its major metabolite nFFA DDI perpetrator potential in vitro and utilized modeling approaches to help translate in vitro observations into in vivo predictions of potential clinical DDI. FFA and nFFA were found to inhibit CYP2D6 in vitro. No noteworthy inhibition of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP3A4/5 was observed in the presence of FFA or nFFA. In the mRNA analysis, both compounds were found to induce CYP2B6 and CYP3A4. Neither compound significantly induced CYP1A2. Neither compound significantly inhibited BCRP, P-gp, OAT1, OAT3, OCT2, MATE1, or MATE2-K. Further evaluation with static mechanistic models\textsuperscript{15} predicted that FFA and nFFA were unlikely to have substantial perpetrator potential at clinically relevant doses, either by inducing CYP450s or by inhibiting transporters or CYP450 enzymes.

FFA undergoes first-pass metabolism in the liver.\textsuperscript{12} Previous evidence in the literature corroborates the findings of CYP2D6 inhibition at high micromolar IC_{50} values by FFA. von Moltke et al.\textsuperscript{35} reported IC_{50} values of 15.1 \mu M for inhibition of CYP2D6-dependent dextromethorphan O-demethylation by both D- and L-isomers isolated from the FFA racemic mixture.\textsuperscript{35} The IC_{50} reported by these authors is closer to our results for nFFA than for FFA. The reason for this difference is unclear but could involve subtle differences in the racemic mixture of FFA and the isolated isomers. These authors also reported weak or negligible inhibitor potential of D- or L-FFA for CYP1A2, CYP2C9, and CYP3A, in accordance with our results.\textsuperscript{35}

Of ASMs commonly used in DS and/or LGS regimens,\textsuperscript{36,37} none are extensively metabolized by CYP2D6.\textsuperscript{7,38} Strimvelis, for example, is metabolized by CYP1A2, CYP2C19, and CYP3A4, and clonazepam is metabolized by CYP3A4 and CYP2C19.\textsuperscript{7,38} Valproate, one of the most commonly prescribed ASMs for DS, is metabolized by CYP2C9, CYP2A6, and CYP2B6, but is not extensively metabolized by CYP2D6.\textsuperscript{39,40}

Time-dependent CYP450 modulation may result in an underprediction of DDI potential.\textsuperscript{41,42} However, neither FFA nor nFFA was a time-dependent (i.e., NADPH-independent) nor a metabolism-dependent (i.e., both time- and NADPH-dependent) inhibitor of any CYP450 enzyme tested in this study according to the standards specified in the FDA 2020 Guidance for Industry.\textsuperscript{15} For CYP2D6, a 30-min preincubation with NADPH-fortified human liver microsomes and escalating FFA doses actually increased the IC_{50} from

| Transporter | IC_{50} (\mu M) | Potential to inhibit transporter | R value |
|-------------|----------------|---------------------------------|---------|
|             | FFA | nFFA | (R) | |
| P-gp        | >100 | >50  | l_{hu}/IC_{50} ≥ 10               | <2.2511 | NA     |
|             | >100 | >50  | C_{max}/IC_{50} ≥ 0.1              | NA     | <0.0037|
| BCRP        | >100 | >50  | l_{hu}/IC_{50} ≥ 10               | <2.2511 | NA     |
|             | >100 | >50  | C_{max}/IC_{50} ≥ 0.1              | NA     | <0.0037|
| OATP1B1     | >300 | >50  | 1+(f_{eg} x l_{hu,ER})/IC_{50} ≥ 1.1 | <1.0012 | <1.0017|
| OATP1B3     | >300 | >50  | 1+(f_{eg} x l_{hu,ER})/IC_{50} ≥ 1.1 | <1.0012 | <1.0017|
| OAT1        | >30  | >50  | I_{max,u}/IC_{50} ≥ 0.1            | <0.0054 | <0.0019|
| OAT3        | >30  | >50  | I_{max,u}/IC_{50} ≥ 0.1            | <0.0054 | <0.0019|
| OCT2        | 19.8 | 5.2  | I_{max,u}/IC_{50} ≥ 0.1            | 0.0082  | 0.0180 |
| MATE1       | 9.0  | 4.6  | I_{max,u}/IC_{50} ≥ 0.1            | 0.0181  | 0.0204 |
| MATE2-K     | >30  | >50  | I_{max,u}/IC_{50} ≥ 0.1            | <0.0054 | <0.0019|

Note: Abbreviation: NA, not applicable.

\textsuperscript{1}IC_{50} is calculated as described in Materials and Methods. See Supplemental Table 1 for transcellular transporter assay conditions.

Table 3: Fenfluramine (FFA) and norfenfluramine (nFFA) potential to inhibit drug transporters—definitions and values of R.
Accumulation of \( ^{14} \text{C}-\text{metformin} \) uptake into HEK-OCT2 cells in the presence of (A) FFA or (B) nFFA. Accumulation of \( ^{14} \text{C}-\text{metformin} \) into HEK-MATE1 cells in the presence of (C) FFA or (D) nFFA

4.5 \( \mu \text{M} \) up to 10 \( \mu \text{M} \), suggesting a slight decrease of in vitro inhibitory potential after prolonged CYP2D6 activation. Conversely, such an increase was not observed with nFFA, where \( IC_{50} \) increased only marginally after 30-min incubation with NADPH when nFFA was the inhibitor. Taken together with the results of the static mechanistic model demonstrating no potential for clinical inhibition, this lack of time- or co-factor-dependent inhibition of CYP2D6 supports that FFA and nFFA are unlikely to substantially inhibit CYP2D6 enzyme activity.

The slight CYP3A4 and CYP2B6 induction observed in our study is unlikely to be clinically relevant per the static mechanistic model predictions. CYP2B6 does not appear to have a high \( f_{\text{in}} \) for any of the commonly used ASMs in LGS or DS.\(^{7}\) CYP3A4 metabolizes numerous xenobiotics including ASMs (e.g., stiripentol, perampanel, felbamate, clobazam, ethosuximide).\(^{7}\) and CYP3A4 induction increases clearance of many xenobiotics.\(^{42,43}\) However, the \( R_2 \) calculations of intrinsic clearance in our study for all evaluable samples are outside established thresholds for significant DDI potential (>0.8).\(^{15,44,45}\)

Our in vitro results suggest that FFA is unlikely to affect drug distribution and/or elimination by inhibiting the major drug transporters.\(^{46}\) The \( R \) values were below the FDA-specified threshold for transporter inhibition of OATP1B1 and OATP1B3 hepatic uptake transporters or OAT1, OAT3, OCT, or MATE2-K renal transporters (Table 3).\(^{15}\) FFA and nFFA inhibition of renal clearance transporters OCT2 and MATE1\(^{47}\) was greater than that observed for the other transporters investigated (Table 3). However, the observed inhibition was not predicted to be clinically meaningful. \( R \) values for OCT2 were below FDA prespecified thresholds of \( \geq 0.1 \); values for FFA and nFFA inhibition of MATE1 were \( <0.0181 \) and \( <0.0204 \), respectively, corresponding to less than the FDA-specified threshold of \( \geq 0.1 \). At clinically relevant doses, neither FFA nor nFFA has significant potential to inhibit renal or hepatic drug transporters.

Our in vitro results align with clinical reports suggesting that FFA is unlikely to have sufficient perpetrator potential when used in combination ASM regimens, although DDI have been reported. A recent clinical study investigated the impact of FFA coadministration on plasma levels of stiripentol, valproate, and clobazam—a common combination regimen prescribed for treating DS.\(^{48}\) \( C_{\text{max}} \) values of valproate, stiripentol, and clobazam, all highly protein-bound drugs,\(^{49,50}\) were not significantly affected by adding FFA.\(^{48}\) In a separate study with single-dose FFA added to steady-state cannabidiol, FFA did not significantly affect the pharmacokinetics of cannabidiol.\(^{48}\) Based on the current study, this result is expected, given that cannabidiol is metabolized by CYP2C19 and CYP3A4,\(^{51}\) neither of which was substantially inhibited or induced by FFA or nFFA in vitro. These clinical results support our in vitro observations that FFA is unlikely to substantially induce or inhibit any CYP450 enzyme at clinically relevant doses used in ASM regimens for LGS and DS.

The primary strength of this study is its rigorous, systematic approach to investigating perpetrator potential of FFA. Previous studies published when FFA was marketed as an anorectic agent were targeted investigations of specific CYP enzymes. By adhering to FDA and EMA Guidance to Industry, we report the most comprehensive, systematic report of FFA and nFFA perpetrator potential published to date.
FFA is a racemic mixture of two enantiomers. Although prior publications have evaluated the enantiomers separately, the clinically used FFA is administered as a racemate and therefore the experimental studies were conducted with the racemic form.

This study has some limitations. It should be noted that pharmacogenetic variants cause affected individuals to be classified as poor, extensive, or ultra-metabolizers of CYP2D6 substrates, as well as CYP2C9, CYP2C19, and CYP3A4 substrates, although data suggest that polymorphism of any individual CYP450 is unlikely to affect FFA pharmacokinetics (Zogenix, data on file). It is unknown how interindividual differences among pharmacogenetic variants of CYP450s and drug transporters could affect local and systemic drug concentrations of FFA.

In conclusion, this study provides a comprehensive examination of the impact of FFA and nFFA on clinically relevant CYP450s and transporter proteins. The in vitro DDI data suggest limited potential for FFA to have significant perpetrator activity in multidrug ASM regimens.

ACKNOWLEDGEMENTS
The authors thank scientists from Enzyme Incubations, Analytical Sciences and Data Processing groups at Sekisui XenoTech for their technical expertise in execution of this study.

This study was funded by Zogenix, Inc. Medical writing and editorial support, funded by Zogenix, was provided by Gregory Kopia, PhD, CMP; Danielle Ippolito, PhD, CMP, MWC; and Dolores Matthews, MEd, ELS, of PharmaWrite, LLC (Princeton, NJ). This manuscript was prepared according to the International Society for Medical Publication Professionals’ “Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3.”

DISCLOSURE
P.M. and B.B. are employees of, and own stock in, Zogenix, Inc., S.S. is a consultant for Zogenix, Inc., B.W.O., M.C., and P.B.L. are consultants for Zogenix, Inc., and are employees of Sekisui XenoTech, LLC.

ETHICAL STATEMENT
This study is exempt from ethics approval.

AUTHOR CONTRIBUTION
Participated in research design: BWO, Conducted experiments: Sekisui XenoTech, LLC, Contributed new reagents or analytical tools: N/A, Performed data analysis: MC, PLB, Wrote or contributed to the writing of the manuscript: PM, SS, BB, MC, PLB, BWO.

DATA AVAILABILITY STATEMENT
Zogenix is in the process of establishing a data sharing policy. Written requests for data by legitimate investigators/researchers/clinicians may be submitted to Zogenix, Inc. These requests will be considered on a case-by-case basis and reviewed for appropriateness.

ORCID
Parthena Martin  https://orcid.org/0000-0002-1169-0495
Maciej Czerwiński  https://orcid.org/0000-0003-0047-7979

REFERENCES
1. Andrade R, Barnes NM, Baxter G, et al. Hydroxytryptamine receptors (version 2019.4) in the IUPHAR/BPS guide to pharmacology database. IUPHAR/BPS Guide Pharmacol CITE. 2019;2019(4):1-31. doi:10.2218/gtopdb/F1/2019.4
2. Lage L, Sullivan J, Knupp K, et al. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2019;394:2243–2254.
3. Nabbout R, Mistry A, Zuberi S, et al. Fenfluramine for treatment-resistant seizures in patients with Dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial. JAMA Neurol. 2020;77:300–308.
4. Aras LM, Isla J, Mingorance-Le Meur A. The European patient with Dravet syndrome: results from a parent-reported survey on antiepileptic drug use in the European population with Dravet syndrome. Epilepsy Behav. 2015;44:104–109.
5. Devinsky O, Patel AD, Cross JH, et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med. 2018;378:1888–1897.
6. Lin JH. CYP induction-mediated drug interactions: in vitro assessment and clinical implications. Pharm Res. 2006;23:1089–1116.
7. Zaccara G, Perucca E. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. Epileptic Disord. 2014;16:409–431.
8. Jahngir MU, Ahmad MQ, Jahangir M. Lennox-gastaut syndrome: in a nutshell. Cureus. 2018;10:e3134.
9. Wirrell EC, Laux L, Donner E, et al. Optimizing the diagnosis and management of Dravet syndrome: recommendations from a North American consensus panel. Pediatr Neurol. 2017;68:18–34.
10. Devinsky O, King L, Schwartz D, Conway E, Price D. Effect of fenfluramine on convulsive seizures in CDKL5 deficiency disorder. Epilepsia. 2021;62:e98–e102.
11. Devinsky O, Verducci C, Thiele EA, et al. Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. Epilepsy Behav. 2018;86:131–137.
12. Bever KA, Perry PJ. Dexfenfluramine hydrochloride: an anorexigenic agent. Am J Health Syst Pharm. 1997;54:2059–2072.
13. Marchant NC, Breen MA, Wallace D, et al. Comparative biodisposition and metabolism of 14C-(-/-)+fenfluramine in mouse, rat, dog and man. Xenobiotica. 1992;22:1251–1266.
14. Zientek MA, Youdim K. Reaction phenotyping: advances in the experimental strategies used to characterize the contribution of drug-metabolizing enzymes. Drug Metab Dispos. 2015;43:163–181.
15. US Food and Drug Administration. In vitro drug interaction studies—cytochrome P450 enzyme- and transporter-mediated drug interactions. Guidance for industry, 2020.
16. Giraud C, Treluyer JM, Rey E, et al. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos. 2006;34:608–611.
17. Morrison G, Crockett J, Blakey G, Sommerville K. A phase 1, open-label, pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects. Clin Pharmacol Drug Dev. 2019;8:1009–1031.
18. Di L. Reaction phenotyping to assess victim drug-drug interaction risks. Expert Opin Drug Discov. 2017;12:1105–1115.
19. Ogilvie BW, Usuki E, Yerino P, Parkinson A. In vitro approaches for studying the inhibition of drug-metabolizing enzymes responsible for the metabolism of drugs (reaction phenotyping) with emphasis on cytochrome P450. In: Rodrigues AD, ed. Drug-drug interactions. Informa Healthcare USA; 2008:231–358.
20. Parkinson A, Ogilvie BW, Buckley DB, Kazmi F, Czerwiński M, Parkinson O. Biotransformation of xenobiotics. In: Klaassen CD, ed. Casarette & Doull’s toxicology, the basic science of poisons. McGraw-Hill Companies Inc; 2013:185–376.
21. Hillgren KM, Keppler D, Zur AA, et al. Emerging transporters of clinical importance: an update from the international transporter consortium. *Clin Pharmacol Ther.* 2013;94:52-63.

22. Beckett AH, Brookes LG. The absorption and urinary excretion in man of fenfluramine and its main metabolite. *J Pharm Pharmacol.* 1967;19(Suppl):425-495.

23. Martin P, Czerwiński M, Limaye PB, et al. In vitro evaluation of fenfluramine and norfenfluramine as victims of drug interactions. *Pharmacol Res Perspect.* 2022;10:e00958. doi:10.1002/prp2.959

24. Haupt LJ, Kazmi F, Ogilvie BW, et al. The reliability of estimating \( k_i \) values for direct, reversible inhibition of cytochrome P450 enzymes from corresponding IC\(_{50}\) values: a retrospective analysis of 343 experiments. *Drug Metab Dispos.* 2015;43:1744-1750.

25. Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. *Toxicol Appl Pharmacol.* 2004;199:193-207.

26. Pearce RE, McIntyre CJ, Madan A, et al. Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. *Arch Biochem Biophys.* 1996;331:145-169.

27. Paris BL, Ogilvie BW, Scheinkoenig JA, Ndikum-Moffor F, Gibson R, Parkinson A. In vitro induction and inhibition of human liver cytochrome p450 enzymes by milnacipran. *Drug Metab Dispos.* 2009;37:2045-2054.

28. Vermeer LMM, Isringhausen CD, Ogilvie BW, Buckley DB. Evaluation of ketoconazole and its alternative clinical CYP3A4/5 inhibitors as inhibitors of drug transporters: the in vitro effects of ketoconazole, ritonavir, clarithromycin, and itraconazole on 13 clinically-relevant drug transporters. *Drug Metab Dispos.* 2016;44:453-459.

29. Izumi S, Nozaki Y, Komori T, et al. Substrate-dependent inhibition of organic anion transporting polypeptide 1B1: comparative analysis with prototypical probe substrates estradiol-17β-glucuronide, estrone-3-sulfate, and sulfobromophthalein. *Drug Metab Dispos.* 2013;41:1859-1866.

30. Harding SD, Sharan JL, Faccenda E, et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2019: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. *Nucleic Acids Res.* 2018;46:D1091-D1106. doi:10.1093/nar/gkx1121

31. Alexander SPH, Christopoulos A, Davenport AP, et al. The concise guide to pharmacology 2021/22: G protein-coupled receptors. *Br J Pharmacol.* 2021;178:S27-S156. doi:10.1111/bjp.15538

32. Alexander SPH, Fabbro D, Kelly E, et al. The concise guide to pharmacology 2021/22: Enzymes. *Br J Pharmacol.* 2021;178:S313-S411. doi:10.1111/bjp.15542

33. Alexander SPH, Kelly E, Mathie A, et al. The concise guide to pharmacology 2021/22: transporters. *Br J Pharmacol.* 2021;178:S512-S513. doi:10.1111/bjp.15543

34. Holford NH. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. *Clin Pharmacokinet.* 1986;11:483-504.

35. von Moltke LL, Greenblatt DJ, Ciraulo DA, et al. Appetite suppressant drugs as inhibitors of human cytochromes P450: in vitro inhibition of P450–2D6 by D- and L-fenfluramine, but not phentermine. *J Clin Psychopharmacol.* 1998;18:338-341.

36. Tagawa A, Cross JH. Treatment of epileptic encephalopathies. *CNS Drugs.* 2013;27:175-184.

37. Wallace A, Wirtell E, Kenney-Jung DL. Pharmacotherapy for Dravet syndrome. *Pediatric Drugs.* 2016;18:197-208.

38. Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. *Expert Rev Neurother.* 2010;10:119-140.

39. Ghodke-Puranik Y, Thorn CF, Lamba JK, et al. Valproic acid pathway: pharmacokinetics and pharmacodynamics. *Pharmacogenet Genomics.* 2013;23:236-241.